Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial

Autor: Claire N. Harrison, Jyoti Nangalia, Rebecca Boucher, Aimee Jackson, Christina Yap, Jennifer O'Sullivan, Sonia Fox, Isaak Ailts, Amylou C. Dueck, Holly L. Geyer, Ruben A. Mesa, William G. Dunn, Eugene Nadezhdin, Natalia Curto-Garcia, Anna Green, Bridget Wilkins, Jason Coppell, John Laurie, Mamta Garg, Joanne Ewing, Steven Knapper, Josephine Crowe, Frederick Chen, Ioannis Koutsavlis, Anna Godfrey, Siamak Arami, Mark Drummond, Jennifer Byrne, Fiona Clark, Carolyn Mead-Harvey, Elizabeth Joanna Baxter, Mary Frances McMullin, Adam J. Mead

Publikováno v: Harrison, C N, Nangalia, J, Boucher, R, Jackson, A, Yap, C, O'Sullivan, J, Fox, S, Ailts, I, Dueck, A C, Geyer, H L, Mesa, R A, Dunn, W G, Nadezhdin, E, Curto-Garcia, N, Green, A, Wilkins, B, Coppell, J, Laurie, J, Garg, M, Ewing, J, Knapper, S, Crowe, J, Chen, F, Koutsavlis, I, Godfrey, A, Arami, S, Drummond, M, Byrne, J, Clark, F, Mead-Harvey, C, Baxter, E J, McMullin, M F & Mead, A J 2023, ' Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial ', Journal of Clinical Oncology : official journal of the American Society of Clinical Oncology . https://doi.org/10.1200/JCO.22.01935

PURPOSE Polycythemia vera (PV) is characterized by JAK/STAT activation, thrombotic/hemorrhagic events, systemic symptoms, and disease transformation. In high-risk PV, ruxolitinib controls blood counts and improves symptoms. PATIENTS AND METHODS MAJIC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18fd7ce9bbaa9e48083024978d50aea3
https://pure.qub.ac.uk/en/publications/fcda774d-04e8-4597-8a71-76d0585a46e6

Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia

Autor: Arief S. Gunawan, Donal P. McLornan, Bridget Wilkins, Katherine Waghorn, Yvette Hoade, Nicholas C. P. Cross, Claire N. Harrison

Publikováno v: Haematologica, Vol 102, Iss 6 (2017)

Externí odkaz: https://doaj.org/article/1b2eb367507b4fa1861c4b11f2ccec2e

O29 Keeping a watchful eye: IgG4-positive lymphoma masquerading as IgG4-related ocular disease

Autor: Yik Long Man, Charlie Hession, Geoffrey Rose, Bridget Wilkins, David Wrench, David D'Cruz

Publikováno v: Rheumatology Advances in Practice. 5

Case report - Introduction IgG4-related disease (IgG4-RD) is increasingly recognised in rheumatology practice. We describe a case of orbital swelling initially diagnosed as IgG4-RD. It was exquisitely steroid responsive and she was treated with 6 yea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4c0828843e74a51c100226650b8d50bb
https://doi.org/10.1093/rap/rkab067.028

The prognosis of

Autor: Alexandra, Clipson, Sharon, Barrans, Naiyan, Zeng, Simon, Crouch, Nicholas F, Grigoropoulos, Hongxiang, Liu, Sylvia, Kocialkowski, Ming, Wang, Yuanxue, Huang, Lisa, Worrillow, John, Goodlad, Jenny, Buxton, Michael, Neat, Paul, Fields, Bridget, Wilkins, John W, Grant, Penny, Wright, Hesham, Ei-Daly, George A, Follows, Eve, Roman, A James, Watkins, Peter W M, Johnson, Andrew, Jack, Ming-Qing, Du

Publikováno v: The Journal of Pathology: Clinical Research

A proportion of MYC translocation positive diffuse large B‐cell lymphomas (DLBCL) harbour a BCL2 and/or BCL6 translocation, known as double‐hit DLBCL, and are clinically aggressive. It is unknown whether there are other genetic abnormalities that

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c7bececa058f08f2d66fdbf4d9ca584b
https://pubmed.ncbi.nlm.nih.gov/27347428

Post cardiac transplantation lymphoproliferative disorder presenting as t(8;14) Burkitt leukaemia/lymphoma treated with low intensity chemotherapy and rituximab

Autor: Kevin, Windebank, Tom, Walwyn, Richard, Kirk, Gareth, Parry, Asif, Hasan, Nick, Bown, Bridget, Wilkins

Publikováno v: Pediatric bloodcancer. 53(3)

Post-transplant lymphoproliferative disorder (PTLD) occasionally presents as Burkitt lymphoma/L3 leukaemia (BLL).We reviewed records of cases of PTLD post-cardiac transplantation (1990-2007) occurring in our unit.There were 15 episodes in 13 patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::41103ac373aef426e0859d324754e8f2
https://pubmed.ncbi.nlm.nih.gov/19459198